Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Gamida Cell ltd
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
University of Rochester
M.D. Anderson Cancer Center
Medical College of Wisconsin
Weill Medical College of Cornell University
Brown University
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Thomas Jefferson University
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
NHS Blood and Transplant
Medical College of Wisconsin
University of California, San Diego
St. Jude Children's Research Hospital
Massachusetts General Hospital
Academic and Community Cancer Research United
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
University of Michigan Rogel Cancer Center
Duke University
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
Columbia University
Academic and Community Cancer Research United
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University